WO2002092066A1 - Preparation antitumorale sans effets secondaires - Google Patents

Preparation antitumorale sans effets secondaires Download PDF

Info

Publication number
WO2002092066A1
WO2002092066A1 PCT/RU2001/000523 RU0100523W WO02092066A1 WO 2002092066 A1 WO2002092066 A1 WO 2002092066A1 RU 0100523 W RU0100523 W RU 0100523W WO 02092066 A1 WO02092066 A1 WO 02092066A1
Authority
WO
WIPO (PCT)
Prior art keywords
patient
radiation
day
treatment
cells
Prior art date
Application number
PCT/RU2001/000523
Other languages
English (en)
Russian (ru)
Inventor
Aleksandr Petrovich Khokhlov
Aleksandr Nikolaevich Dotsenko
Original Assignee
Aleksandr Petrovich Khokhlov
Aleksandr Nikolaevich Dotsenko
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2001113007A external-priority patent/RU2182480C1/ru
Priority claimed from RU2001124366A external-priority patent/RU2197957C1/ru
Application filed by Aleksandr Petrovich Khokhlov, Aleksandr Nikolaevich Dotsenko filed Critical Aleksandr Petrovich Khokhlov
Publication of WO2002092066A1 publication Critical patent/WO2002092066A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Definitions

  • ⁇ se ⁇ iv ⁇ u ⁇ levye (or ⁇ iv ⁇ blas ⁇ mnye) ⁇ e ⁇ a ⁇ a ⁇ y ⁇ azdelyayu ⁇ on ⁇ yad g ⁇ u ⁇ , is ⁇ dya of i ⁇ ⁇ imiches ⁇ y s ⁇ u ⁇ u ⁇ y, me ⁇ anizma deys ⁇ viya, is ⁇ chni ⁇ v ⁇ lucheniya: al ⁇ ili ⁇ uyuschie vesches ⁇ va, an ⁇ ime ⁇ ab ⁇ li ⁇ y, an ⁇ ibi ⁇ i ⁇ i, and ag ⁇ nis ⁇ y an ⁇ ag ⁇ nis ⁇ y g ⁇ m ⁇ n ⁇ v, and al ⁇ al ⁇ idy d ⁇ ugie s ⁇ eds ⁇ va ⁇ as ⁇ i ⁇ eln ⁇ g ⁇ ⁇ is ⁇ zhdeniya.
  • SIGNIFICANT FOX (DR. 26)
  • One of the main non-essential effects of chemotherapy is the inhibition of abuse, which requires the elimination of waste; It is necessary to take into account that the depression of hematopoiesis is amplified by combined therapy - a combination of radiation therapy and other. Often there is sickness, vomiting, miscarriage, diarrhea, alopecia and other harmful phenomena are possible. Negative antibiotics have a good chance of caring for - (docubicin and others.), Non-negligent and non-toxic. With the use of separate drugs, the possible development of hyperuricemia. Estrogen, androgen, their analogs and antagonists can cause hormonal diseases. One of the adverse effects of many medical devices is their immune health, weaknesses and weaknesses.
  • SIGNIFICANT FOX (DR. 26) issled ⁇ va ⁇ eli of Ge ⁇ manii ( ⁇ ez ⁇ ka ⁇ and d ⁇ ..) ⁇ az ⁇ ab ⁇ ali an ⁇ i ⁇ u ⁇ lev ⁇ e s ⁇ eds ⁇ v ⁇ , ⁇ eds ⁇ avlyayuschee s ⁇ b ⁇ y tsi ⁇ s ⁇ a ⁇ i ⁇ in li ⁇ s ⁇ maln ⁇ y ⁇ me, d ⁇ lni ⁇ eln ⁇ s ⁇ de ⁇ zhaschy ⁇ n ⁇ as ⁇ i ⁇ uyuschy agen ⁇ , vyb ⁇ anngy of g ⁇ u ⁇ y: y ⁇ d, gad ⁇ liny or magne ⁇ i ⁇ . (Pat.
  • SIGNIFICANT FOX (DR. 26) The basic for the creation of such a material was served by deep-seated sharks, known from ancient times. The fishes of the ancient Japan called it "8th or "panacea.” At the sharks, they were lodging at the bottom of the bay, 1000 meters deep, there was a large amount of meat. They especially appreciated their fat, which made them feel relaxed to improve their well-being. ⁇ 1758 the famous celebrity botanic and malaise of the land of the Republic of Linnaeus announced a great value for health and the medical significance of the deep shark extract. In the Mediterranean, the “miraculous oil” centuries were different, but different sources of power and energy.
  • Squalene is an effective compound for the treatment of carriers of the C virus virus, it improves the virgous replication of the C virus virus (the patent 5858389, 12.01.1999).
  • SIGNIFICANT FOX (DR. 26) A detailed study was made of the cosmetic and dermal properties of the right and left side (Pat. ⁇ 5079003, 1992). Particularly, it is discreetly affecting the use of each other [6].
  • ⁇ ⁇ slednem ⁇ isan ⁇ ch ⁇ v ⁇ zdeys ⁇ vie ⁇ z ⁇ na on s ⁇ valen ⁇ iv ⁇ di ⁇ ⁇ ⁇ yavleniyu in ⁇ sledneg ⁇ ⁇ a ⁇ i ⁇ ⁇ lezny ⁇ sv ⁇ ys ⁇ v, ⁇ a ⁇ an ⁇ iba ⁇ e ⁇ ialnaya, ⁇ ungitsidnaya and d ⁇ ugie ⁇ leznye a ⁇ ivn ⁇ s ⁇ i, ⁇ n m ⁇ lse ⁇ by ⁇ is ⁇ lz ⁇ van ⁇ i s ⁇ lnechny ⁇ and d ⁇ . thermal burns.
  • the inventive invention also refers to the ⁇ C with other well-known impulse devices, where ⁇ C is a property of the product
  • a method for the production of EC is obtained, which is another aspect of the invention, and is used as a result of the use of industrial waste oil (derived from waste oil)
  • an active acid selected from the group: Exposure, exposure to water, exposure to the acid.
  • the active form of acid is 3 hours to 24 hours.
  • Table 1 shows the change in the level of absorption when activated and the treatment of UV radiation at a temperature of 90 ° C during different times of exposure.
  • SIGNIFICANT FOX (DR. 26) Further processing is discarded by UV radiation (over 12 hours), resulting in the formation of a white seedlings, through the treatment of surplus material, which indicates that there is no evidence of material waste.
  • Table 2 shows the accumulation of aldehydes (in percentage), depending on the efficiency of the process, the temperature is 90 ° ⁇ .
  • the optimum time for heating may be 1-6 hours.
  • Table 4 shows the change in the absorption level and the activation of the exposure to radiation in the UF-sector. In the table it is visible that the optimal level of absorption is observed during processing within 3-6 hours. If the time of exposure to U-rays increases for more than 12 hours, the activated component is destroyed, resulting in a loss of contact with the unit.
  • 5 ⁇ full 5 provides information on the dependence of the volume and the density of the device when it is activated by the UF-radiation while the UF is operating.
  • the preparation was dissolved in dimethyl sulfoxide ( ⁇ ) and added to the culture after 1 day after the removal of the cells. The result was evaluated on the second day of growth (1 day on the product) and 4-5 on the basis of growth (3-4 days on the product).
  • ⁇ ⁇ igu ⁇ e 1 ⁇ eds ⁇ avlen ⁇ influence ⁇ S (I) and Hc (II) to the line ⁇ u ⁇ levy ⁇ ⁇ le ⁇ 1X929, here ⁇ azan ⁇ change s ⁇ s ⁇ i sin ⁇ eza D ⁇ ( ⁇ ve ⁇ i ⁇ ali -% s ⁇ s ⁇ i sin ⁇ eza D ⁇ ⁇ u ⁇ levy ⁇ ⁇ le ⁇ in s ⁇ avnenii with ⁇ n ⁇ lem) ⁇ d deys ⁇ viem ⁇ S and Hc.
  • ⁇ C has a pronounced statistical effect, inhibiting after 24 hours the synthesis of up to 3% of the original level.
  • ⁇ figure 2 is shown to be cleaned under the influence of ⁇ ( ⁇ ) and ⁇ ( ⁇ ) is the average index of 10 divisions. It can be seen that the device stimulated the expansion of the 1X929 cell plugs, while it was possible to remove it from the power supply.
  • Figure 3 shows the results of studies of the influence of ⁇ (I) and ⁇ (II) on the line of positive cells of gle ⁇ 12 after 3 hours after the introduction.
  • the study of the speed of the D synthesis (% of the return) showed that the synthesis of the D completely is blocked by C (I).
  • Fig. 4 takes care of the easy-to-clean armaC 12 line cells after 3 hours after the introduction of ⁇ ( ⁇ ) and ⁇ ( ⁇ ) preparations. Influenced by ⁇ C (I), there is a decrease in the number of tumor cells in the environment.
  • Figure 5 shows the rate of synthesis of the protein (% of the protein) for the SC 12 line cells after 3 hours after the introduction of the SC ( ⁇ ) and SC ( ⁇ ) preparations.
  • the protein synthesis in the ocellular cells is very significantly reduced by the action of the EC, in contrast to the operation of the cell.
  • Concentrations of 6 ⁇ L (accessory size 830 x 10 cells) for the first days of growth caused a partial degeneration of the battery, during the unloading ⁇
  • a complete degeneration of the cell culture occurred.
  • the death of the cell in the main case occurred at a rate of: the appearance of the nucleus, reduction of the size, ezinophilia of the cytoplasm.
  • Figure 7 shows the receptacle of the genome 62 under the influence of ⁇ ( ⁇ ) and ⁇ ( ⁇ ), which has been reduced by the action of ⁇ in comparison with ⁇ .
  • the protein synthesis rate in the line of the genome of the receptacle 62 was delivered after 24 hours after the introduction of SC ( ⁇ ) and SC ( ⁇ ), significantly reducing the effect of the action.
  • the native standard does not have a significant effect on the growth of the tissue.
  • the preparation showed expressed cytotoxicity.
  • the cell end decreased significantly (up to 69%). Separate portions of open cells were observed.
  • the object is the cells of 12C 12 ( Canal ⁇ ⁇ ⁇ ⁇ ).
  • figure P shows the average of 10 values (% of the value). It is shown (and the same follows from the analysis of the histories), which doesn’t have a significant effect on the cells of the IC 12.
  • mice from g ⁇ u ⁇ ⁇ n ⁇ lny ⁇ and lechenny ⁇ zhiv ⁇ ny ⁇ , izvle ⁇ ali astsi ⁇ iches ⁇ uyu lsid ⁇ s ⁇ and ⁇ sle mn ⁇ g ⁇ a ⁇ n ⁇ g ⁇ ⁇ mshaniya b ⁇ yushn ⁇ y ⁇ l ⁇ s ⁇ i ⁇ izi ⁇ l ⁇ giches ⁇ im ⁇ as ⁇ v ⁇ m ⁇ dschi ⁇ yvali ⁇ bschee chisl ⁇ ⁇ u ⁇ levy ⁇ ⁇ le ⁇ in b ⁇ yushn ⁇ y ⁇ l ⁇ s ⁇ i msh ⁇ i with ⁇ m ⁇ schyu ⁇ ame ⁇ y G ⁇ yaeva.
  • a further aspect of the invention is the use of a drug for the implementation of a method for the treatment of human patients.
  • the EC uses a dose in the dose effective for receiving the best effect.
  • This dose may be different for different factors and the severity of the disease in the range of 0.1-1.0 ml / kg weight and is taken for 4-5 days in a day. Treatment may be avoided for a few weeks to a few months.
  • the average optimal dose is usually 0.4–0.5 ml / kg; the most convenient way to do this is to treat each patient individually.
  • the invention is illustrated by the examples of patients with other forms of the disease.
  • EXAMPLE 1 A large ⁇ , 53 years old, was released in a severe condition on May 15, 2000, in a satisfactory condition with complaints of an unresponsiveness. He considers himself to be painful for the last 4 months, when, without a visible reason, he got a leak after a defecation in the volume of 10-15 ml, then a pain syndrome appeared. No enteric events have been noted.
  • moderate anemia is 95 g / l.
  • the patient was treated with a C ⁇ drug (squeezed, irradiated with UF for 3 hours; daily doses of 20 ml or 4 ml 5 times a day).
  • Mr. Bolshoi 64 years old, lost his stay in a cold hospital on May 15, 2000, with complaints of mild, lingering pains in the left half of the hill, which was more painful. He considers himself to be painful for the past 8 months, when after a cleaned enema, a fresh infection appeared in the calyx in the amount of 30 ml. After this, the acquisition was not sent. However, after 2 weeks, there were persistent aching pains in the left half of the body with irradiation in the lumbar region. He went to the hospital for examination and treatment.
  • Clinical diagnosis first letter ⁇ 2 ⁇ 0 .
  • the patient was treated with a ⁇ C drug (squalene, active therapy).
  • the daily dose is 30 ml, at least 5 times a day, at 6 ml.
  • the after-treatment went off without any particularities.
  • the patient is prepared for checkout.
  • narcotic analgesics medicament, multimodal
  • Biography 14, 28, 42, 56, 84 days. 14th day - a citulis of more than 30% of positive voltage; 28 day - citation of more than 50% of healthy cell; 42 day - citation of more than 70% of healthy cells; 56 day - citulis more than 80% of safe cell; 84 day - citation of more than 90% of healthy cell; Conclusion: phenomena of degradation of the observed.
  • Example 5 Bolshoi ⁇ ., 68 years old, was released in a severe condition on 18 October 2000 with complaints of physical dysfunction and physical disruption Bleu syndrome is not.
  • Diagnosis after an early biopsy the case of the gastric department of the stomach. A high-grade tubular adenocarcinoma.
  • the results are listed below.
  • Biopsy results 14th day - citation for more than 30% of healthy cells; 28 day - citation of more than 60% of healthy cells; 42 day - cystylosis more than 70% of good cell health.
  • Another aspect of the invention is the discovery of a new product, the ability to loosen and / or disarm the device.
  • ⁇ a ⁇ yadu s ⁇ s ⁇ etsi ⁇ iches ⁇ im ⁇ m ⁇ zyaschim influence on ⁇ u ⁇ li, s ⁇ v ⁇ emennye ⁇ iv ⁇ u ⁇ levye s ⁇ eds ⁇ va deys ⁇ vuyu ⁇ on d ⁇ ugie ⁇ ani and sis ⁇ emy ⁇ ganizma, ch ⁇ with ⁇ dn ⁇ y s ⁇ ny, ⁇ busl ⁇ vlivae ⁇ i ⁇ nezhela ⁇ elnye ⁇ b ⁇ chnye e ⁇ e ⁇ y and with d ⁇ ug ⁇ y - ⁇ zv ⁇ lyae ⁇ is ⁇ lz ⁇ va ⁇ i ⁇ in d ⁇ ugi ⁇ ⁇ blas ⁇ ya ⁇ medicine.
  • a significant disadvantage of the device is the small selectivity of the battery.
  • D ⁇ lni ⁇ eln ⁇ y task nas ⁇ yascheg ⁇ iz ⁇ b ⁇ e ⁇ eniya yavlyae ⁇ sya ⁇ a ⁇ lse s ⁇ zdanie unive ⁇ saln ⁇ g ⁇ ⁇ e ⁇ a ⁇ a ⁇ a not imeyuscheg ⁇ ⁇ b ⁇ chn ⁇ g ⁇ deys ⁇ viya, ⁇ y not ⁇ l ⁇ himself ⁇ bladae ⁇ ⁇ iv ⁇ u ⁇ lev ⁇ y a ⁇ ivn ⁇ s ⁇ yu, n ⁇ ⁇ a ⁇ zhe very e ⁇ e ⁇ ivn ⁇ sniyasae ⁇ ⁇ b ⁇ chnye phenomenon ⁇ i is ⁇ lz ⁇ vanii ⁇ azlichnzh ⁇ iv ⁇ u ⁇ levzh s ⁇ eds ⁇ v, ⁇ a ⁇ ⁇ imi ⁇ e ⁇ a ⁇ ev ⁇ iches ⁇ i ⁇ , ⁇ a ⁇ and ⁇ adi ⁇ iz ⁇ nzh.
  • Another property of the present invention is the method of weakening and / or eliminating the harmful effects of both chemical and radioactive substances. As a result, a patient is assigned an effective EC in an effective manner.
  • the product provides a direct preparation of the necessary effect.
  • the optimal dose is 0.3 ml / kg body weight.
  • the duration of the trip may be different from 7 to 200 days, in many cases the effect is reached from 7 to 20 days.
  • the test device was operated on more than 300 patients with different patient care when using a chemical device, a device and a radio.
  • the drug is effective for patients with gastrointestinal tract, intestines, lungs, adenocarcinoma, metabolic disease, and metabolic disease.
  • the liver is at the right side of the arc.
  • the affected syndrome was controlled by the introduction of narcotic analgesics (medicament, multimodal) up to 7-8 times a day.
  • narcotic analgesics medicament, multimodal
  • the patient noted a complete lack of diabetes, with food, it turned out that the patient was sick and vomiting.
  • Assignment of chemotherapy (desububimycin, mitomycin) once in 3 days internally

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une nouvelle préparation antitumorale n'ayant pas d'effets secondaires sur la base d'un squalène activé (SA). On active un squalène natif ou synthétique pour obtenir des dérivés ayant une propriété d'inhibition sélective de la synthèse d'ADN des cellules tumorales sans être toxiques envers les cellules saines. L'activation du squalène se fait au moyen du traitement thermique, de l'irradiation par rayons UV ou IR ou par l'application d'une forme active d'oxygène telle que l'ozone ou le peroxyde d'hydrogène. Le SA ainsi obtenu est utilisé pour traiter les tumeurs de diverses natures, y compris la leucose et les phénomènes métastasiques ainsi que pour affaiblir et/ou éliminer les effets secondaires lors d'une thérapie antitumorale. En outre, le SA est utilisé pour potentialiser certaines préparations antitumorales chimiothérapeutiques ou basées sur des radionucléides.
PCT/RU2001/000523 2001-05-16 2001-12-04 Preparation antitumorale sans effets secondaires WO2002092066A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
RU2001113007 2001-05-16
RU2001113007A RU2182480C1 (ru) 2001-05-16 2001-05-16 Противоопухолевый препарат и способ его получения
RU2001124366 2001-09-04
RU2001124366A RU2197957C1 (ru) 2001-09-04 2001-09-04 Препарат и способ устранения побочного действия противоопухолевых средств

Publications (1)

Publication Number Publication Date
WO2002092066A1 true WO2002092066A1 (fr) 2002-11-21

Family

ID=26654085

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2001/000523 WO2002092066A1 (fr) 2001-05-16 2001-12-04 Preparation antitumorale sans effets secondaires

Country Status (1)

Country Link
WO (1) WO2002092066A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102871965A (zh) * 2011-07-13 2013-01-16 郭增平 一种治疗肿瘤药物喷雾剂的制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61148119A (ja) * 1984-12-21 1986-07-05 Nissei Marine Kogyo Kk 制癌剤
JPH0680572A (ja) * 1992-09-01 1994-03-22 Tsumura & Co 発癌予防剤
US5308875A (en) * 1990-05-08 1994-05-03 Nippon Petrochemicals Co., Ltd. Therapeutic coolant for the local treatment of burn
RU2034562C1 (ru) * 1994-06-27 1995-05-10 Александр Васильевич Тихонов Способ подавления роста опухолевых клеток и средство для его осуществления
EP0766960A1 (fr) * 1995-04-21 1997-04-09 Sekisui Kagaku Kogyo Kabushiki Kaisha Preparations a usage externe destinees au traitement de dermatoses

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61148119A (ja) * 1984-12-21 1986-07-05 Nissei Marine Kogyo Kk 制癌剤
US5308875A (en) * 1990-05-08 1994-05-03 Nippon Petrochemicals Co., Ltd. Therapeutic coolant for the local treatment of burn
JPH0680572A (ja) * 1992-09-01 1994-03-22 Tsumura & Co 発癌予防剤
RU2034562C1 (ru) * 1994-06-27 1995-05-10 Александр Васильевич Тихонов Способ подавления роста опухолевых клеток и средство для его осуществления
EP0766960A1 (fr) * 1995-04-21 1997-04-09 Sekisui Kagaku Kogyo Kabushiki Kaisha Preparations a usage externe destinees au traitement de dermatoses

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102871965A (zh) * 2011-07-13 2013-01-16 郭增平 一种治疗肿瘤药物喷雾剂的制备方法

Similar Documents

Publication Publication Date Title
WO2005004903A1 (fr) Methode de traitement de maladies oncologiques
WO2005039636A1 (fr) Produit pour potentialiser les effets curatifs et intensifier l'action d'un medicament
WO2005007187A1 (fr) Methode de traitement des maladies oncologiques, infectieuses et somatiques, procedes de controle de l'efficacite du traitement, agents et compositions pharmaceutiques associes
WO1994001099A1 (fr) Composition pharmaceutique presentant des actions anti-alcool stimulant le metabolisme de l'energie, stimulant les fonctions de production et de secretion d'acide de la membrane muqueuse de l'estomac, et presentant egalement des actions radioprotectrice et anti-cholera
WO1993013764A1 (fr) Preparation pharmaceutique a action antistress, de prevention du stress et nootrope
WO2003040723A1 (fr) Procede de rehabilitation de l'organisme en cas d'infection virale lente
WO2003072124A1 (fr) Methode d'induction de differentiation cellulaire
EP0363491A4 (en) Bacterial preparation for prophylaxis and treatment of inflammatory processes and allergic diseases
Spittle A simple and effective treatment for AIDS related Kaposi's sarcoma.
Kellogg Autointoxication; Or, Intestinal Toxemia
WO1994028153A2 (fr) Adn de faible masse moleculaire tiree de laitance d'esturgeon, procede d'obtention de l'adn et preparation pharmaceutique a base de celui-ci
WO2002092066A1 (fr) Preparation antitumorale sans effets secondaires
WO2004043485A1 (fr) Composition presentant des proprietes antioxydantes, procede de production d'un polypeptide et methode de traitement
EP0680756B1 (fr) Utilisation d'une combinaison d'antinéoplastones pour la fabrication d'un médicament pour le traitement de la neurofibromatose
Salem et al. Dehydroemetine in acute amoebiasis
US20030077257A1 (en) Method for preventing and curing diseases of an immune system and a remedy for carrying out said method
US20090238796A1 (en) Preparation for treatment of non-infectious inflammatory intestinal diseases
WO2004064849A1 (fr) Produit normalisant la structure et les fonctions des organes et tissus, stimulant les reparations des lesions et possedant une activite antivirale
Graham-Pole et al. Myeloablative treatment for children with metastatic neuroblastoma supported by bone marrow infusions: Progress and problems
Hutchison The elements of medical treatment
RU2197957C1 (ru) Препарат и способ устранения побочного действия противоопухолевых средств
WO1999016456A1 (fr) Preparation ayant une activite biologique, complexe de preparations et procede de stimulation immunologique
WO2003105875A1 (fr) Immunostimulateur presentant une activite anticancereuse et procede de preparation correspondant
RU2200567C1 (ru) Способ профилактики и лечения желудочно-кишечных болезней новорожденных телят
Szatlóczky Cause, diagnosis, and chemotherapy of lactose intolerance

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP